Stryker and Max Smart Hospital, Saket Partner to Advance Surgeon Training and Education in Robotic-Arm Assisted Joint Replacement

IMT News Desk
IMT News Desk
· 2 min read
Stryker & Max Hospital, Saket have partnered to create a robotic‑arm assisted joint replacement training and education center

Stryker and Max Smart Super Speciality Hospital, Saket, announced a strategic collaboration to advance surgeon training, clinical education, and patient care in robotic-arm-assisted joint replacement in India.

As part of this collaboration, Max Smart Super Speciality Hospital, Saket, will serve as a training and education center for orthopaedics. The collaboration aims to support the evolving joint replacement ecosystem by developing long-term clinical expertise and improving access to technology-enabled treatment approaches.

Speaking on the collaboration, Mr. Abhay Soi, Chairman and Managing Director, Max Healthcare Institute Ltd., said, “This collaboration with Stryker is an important step towards strengthening orthopaedic care delivery in India through structured training frameworks and advanced clinical education. The development of Max Smart Super Speciality Hospital, Saket, as a training and education center for orthopaedics reflects our focus on enabling wider access to next-generation orthopaedic care and creating long-term impact through skill development and collaborative learning.”

Adding, Dr. Ramneek Mahajan, Chairman – Orthopaedics, Joint Replacement & Chief Robotic Joint Replacement, Max Smart Super Speciality Hospital, Saket, stated, “Robotic-arm assisted joint replacement represents an important advancement in orthopaedic surgery, offering greater precision, personalized planning and potentially improved recovery outcomes for patients. However, the true impact of technology depends on how effectively it is adopted and practiced. Through this training and education center, we aim to create a robust platform for hands-on surgeon training and dissemination of best practices that can further strengthen robotic-assisted joint replacement in India.”

“At Stryker, we are working closely with leading healthcare institutions across Asia Pacific to help scale robotics-assisted surgical capability, invest in surgeon training and support the growing demand for joint replacement,” shared John Collings, President, APAC, Stryker

“As osteoarthritis and joint disease rise in India and technologies like robotic-arm assisted joint replacement advance, surgeon training must keep pace. This training and education center will help bridge the skill gap and enable evidence-based care at scale, shared Aman Rishi, Vice President & General Manager – India, Stryker. It reflects Stryker’s long-term commitment to India and our vision to make robotic joint replacement more accessible and scalable across the country.” 

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk